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Abstract 
C16orf57 encodes a human protein of unknown function, and mutations in the gene 
occur in poikiloderma with neutropenia (PN), which is a rare, autosomal recessive disease. 
Interestingly, mutations in C16orf57 were also observed among patients diagnosed with 
Rothmud-Thomson syndrome (RTS) and dyskeratosis congenita (DC), which are caused by 
mutations in genes involved in DNA repair and telomere maintenance. A genetic screen in 
Saccharomyces cerevisiae revealed that the yeast ortholog of C16orf57, USB1 (YLR132C), is 
essential for U6 snRNA biogenesis and cell viability. Usb1 depletion destabilized U6 snRNA, 
leading to splicing defects and cell growth defects, which was suppressed by the presence of 
multiple copies of the U6 snRNA gene, SNR6. Moreover, Usb1 is essential for the generation 
of a unique feature of U6 snRNA, namely the 3' terminal phosphate. RNAi experiments in 
human cells followed by biochemical and functional analyses confirmed that, similar to yeast, 
C16orf57 encodes a protein involved in the 2',3'-cyclic phosphate formation at the 3' end of 
U6 snRNA. Advanced bioinformatics predicted that C16orf57 encodes a phosphodiesterase, 
whose putative catalytic activity is essential for its function in vivo. Our results predict an 
unexpected molecular basis for PN, DC, and RTS, and provide insight into U6 snRNA 3’end 
formation.  
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Introduction 
Poikiloderma with neutropenia (PN) is a rare, autosomal recessive skin condition 
(OMIM 604173) in which mutations in the C16orf57 gene were found (Volpi et al. 2010). 
C16orf57 encodes a protein of unknown molecular function. To date, 19 distinct C16orf57 
mutations have been identified in 31 patients with PN (for details see supplementary Table 
S1; Arnold et al. 2010; Tanaka et al. 2010; Volpi et al. 2010; Clericuzio et al. 2011; Colombo 
et al. 2012) all of which lead to the generation of truncated, and most likely nonfunctional, 
proteins. C16orf57 is also mutated in a subset of patients diagnosed with dyskeratosis 
congenita (DC) and Rothmund-Thomson syndrome (RTS) (Walne et al. 2010; Piard et al. 
2011). Interestingly, DC and RTS share many similar clinical phenotypes with PN; however, 
mutations in C16orf57 can be used as molecular markers that allow for correct diagnosis 
(Piard et al. 2011).  DC is often caused by mutations in factors involved in telomere 
maintenance (Armanios 2009), while RTS is primarily caused by mutations in the RECQL4 
DNA helicase involved in DNA repair and replication (Larizza et al. 2010). The correlation 
between these diseases and mutations in C16orf57 suggests that it may encode a protein 
involved in ensuring genome integrity. However, no changes in telomere length were 
observed in RTS patients with C16orf57 mutations (Walne et al. 2010), which raised the 
question of what the physiological function of C16orf57 is. 
In this study, we took advantage of an unbiased yeast genetic screen to investigate the 
function of C16orf57. Our results, coupled with functional experiments in yeast and human 
cells as well as bioinformatic analyses, indicated that C16orf57 and its yeast ortholog USB1 
(for U Six Biogenesis 1) may encode the long sought U6 snRNA phosphodiesterase, which is 
an essential enzyme in the biogenesis of the splicing apparatus. Splicing is the process of 
removing introns and is an essential step in mRNA maturation (Wahl et al. 2009). In 
4 
 
eukaryotes, this process is mediated by a dynamic macromolecular assembly composed of 
five small nuclear ribonucleic acid particles (snRNAs) and associated proteins, which are 
together referred to as small nuclear ribonuclearproteins (snRNPs, U1, U2, U4, U5, U6). The 
U1, U2, U4, and U5 snRNAs are transcribed by RNA polymerase II and subsequently 
capped, similar to other transcripts. U6 snRNA, however, is transcribed by RNA polymerase 
III and never leaves the nucleus. Mature U6 is involved in catalysis of the splicing 
transesterification reactions and 5' splice site selection (Kandels-Lewis and Seraphin 1993; 
Lesser and Guthrie 1993; Valadkhan 2010). The U6 snRNA undergoes large conformational 
changes during splicing. At the beginning of the splicing cycle, U1 and U2 snRNPs base pair 
with the pre-mRNA. The U6 snRNA then, together with U4 and U5 snRNAs as a part of 
assembly called the U4/U6.U5 tri-snRNP, enters the pre-spliceosome. Prior to the splicing of 
the pre-mRNA, U1 and U4 snRNAs dissociate from the complex, which allows U6 snRNA to 
base pair with U2 snRNA and the pre-mRNA to form an active site of the spliceosome 
(Valadkhan 2010). After the catalytic splicing steps, U6 snRNA dissociates from the 
spliceosome with the U6-associated LSM proteins. The proper recycling of U6 snRNA 
requires base pairing with U4 snRNA, which is promoted by Prp24, another U6 snRNP 
protein. The cycle is completed when U5 snRNP is recruited to form the U4/U6.U5 tri-
snRNP. 
In addition to the general mechanism of mRNA splicing, there is substantial research 
regarding the regulation and processing of U6 snRNA itself (Patel and Bellini 2008). 
Transcription of U6 snRNA terminates at a uridine tract, which is the typical RNA 
polymerase III termination signal, similar to other transcripts, such as tRNAs and 5S rRNA. 
In humans, the U6 snRNA is post-transcriptionally oligouridynylated by a specific poly(U) 
polymerase (TUTase) (Trippe et al. 2003; Trippe et al. 2006). Interestingly, the last nucleotide 
of approximately 90% of human U6 snRNAs in the cell is modified to form a terminal 2',3'-
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cyclic phosphate (U>P) (Lund and Dahlberg 1992; Schutz et al. 2010). On the other hand, in 
yeast, uridines at the 3' end of U6 snRNA are generated by transcription and the RNA 
molecule is terminated with a 2' or 3' phosphate moiety or hydroxyl groups (Lund and 
Dahlberg 1992). It has been suggested that this U6 snRNA modification is required for the 
proper assembly of the mature snRNP (Gu et al. 1997). Similar to most polymerase III 
transcripts, the nascent U6 snRNA is bound by La antigen and the modification of its 3' end 
promotes the interaction between the RNA and the heptameric ring of LSM proteins (Pannone 
et al. 2001). It has also been suggested that the modification of U6 snRNA 3' end takes place 
dynamically during every spliceosome assembly and disassembly; however, the function of 
such a mechanism in splicing remains obscure (Tazi et al. 1993).  
Despite our understanding of RNA splicing and the role of U6 snRNA in this essential 
process, the enzymes responsible for modifying the U6 snRNA 3' end in yeast and humans 
remain unknown. In this study, we identified C16orf57 (hUsb1) as a putative 
phosphodiesterase essential for the generation of the cyclic phosphate at the 3' end of U6 
snRNA. The C16orf57 gene product is therefore a factor involved in the biogenesis of the 
pre-mRNA splicing apparatus, which would have been extremely difficult to identify had it 
not been for its yeast ortholog. We propose a model where Usb1/hUsb1 acts as an RNase 
responsible for the removal of the terminal nucleotides from the U6 transcript, leading to 
formation of the mature snRNA. 
 
Results 
Usb1 depletion causes in vivo splicing defects and loss of U6 snRNA 
The C16orf57 gene is evolutionarily conserved in all major eukaryotic phyla with an 
ortholog in yeast, YLR132C, encoding yeast Usb1 (Fig. S1), which, similar to its human 
counterpart, has no annotated function. In order to determine the role of Usb1, we first studied 
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its role in yeast growth. We constructed a GAL::USB1 strain, where the expression of USB1 is 
under the galactose-inducible GAL1 promoter. In the presence of galactose, Usb1 is produced, 
whereas in glucose-rich media, the GAL1 promoter is repressed, leading to a depletion of 
Usb1 protein. Using this strain, we confirmed that Usb1 was essential for yeast viability, and 
its metabolic depletion led to a growth defect (Fig. 1A). To gain insight into the function of 
Usb1, we next performed a multicopy suppressor screen using the GAL::USB1 strain. The 
GAL::USB1 strain was transformed with a yeast multicopy library, plated on selective media 
with galactose as the sole carbon source, and then transferred to restrictive, glucose-rich 
media to suppress USB1 expression. We screened 10,000 clones and isolated 30 colonies that 
were able to restore growth on glucose media. Sequencing the plasmids isolated from these 30 
colonies identified the wild-type (WT) USB1 or SNR6 gene, encoding U6 snRNA, as the 
suppressors of the growth defect caused by Usb1 depletion (Fig. 1B). This result strongly 
suggested that Usb1 might be involved in U6 snRNA regulation and play a role in splicing. 
To test the idea that Usb1 might play a role in splicing, we assayed for splicing defects 
caused by Usb1 depletion. RNA isolated from WT and GAL::USB1 strains at various time 
points after the induction of Usb1 depletion was analyzed by northern blot (Fig. 1C). We first 
analyzed the U3 snoRNA, which contains spliceosomal intron as pre-mRNAs. We observed 
an accumulation of U3 snoRNA precursors upon Usb1 depletion, confirming the involvement 
of Usb1 in splicing. We next investigated the steady-state levels of snRNAs by northern blots 
and observed that the levels of U6 snRNA decreased as Usb1 depleted. Importantly, the levels 
of U1, U2, U4, and U5 snRNAs remained unaffected, indicating that Usb1 had a specific role 
in U6 snRNA regulation (Fig. 1C and Supplementary Fig. S2). In order to further analyze the 
splicing defects caused by Usb1 depletion, we performed splicing reactions using extracts 
from WT and Usb1-depleted cells to splice RP51a pre-mRNA in vitro. Splicing activity of the 
Usb1-depleted extracts grown in repressive YPD media for 8 h or longer was significantly 
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lower than that of the WT extracts (Fig. 1D and 1E). Importantly, low splicing efficiency of 
the Usb1-depleted extracts was partially rescued by the addition of U6 snRNA isolated from a 
TAP-purified Prp24 fraction to the splicing reactions (Fig. 1D and 1E). At the 10 and 12 h 
time points, the rescue  efficiency was low, however the excised introns were clearly visible. 
This indicated that the splicing reaction took place and that the amount of spliced introns was 
higher after supplementation with purified U6 snRNA. Our data suggest that the main 
function of Usb1 is to regulate U6 snRNA biogenesis rather than the splicing reaction itself 
(Fig. 1D, lanes 9-12, 17-20, 25-28 and 1E).  
Usb1 is essential for U6 snRNA stability 
Since Usb1 depletion causes splicing defects and reduction in U6 snRNA levels, we 
investigated whether Usb1 is a part of the U6 small nuclear ribonucleoprotein (snRNP) or its 
assembly intermediates. We performed IgG affinity purification using a Usb1 TAP strain 
followed by gel filtration and mass spectrometry. Our results clearly showed that Usb1 
behaved as a monomer (Supplementary Fig. S3A-B) and was not a part of any stable 
macromolecular complex under our purification conditions. We then tested if Usb1 was 
involved in snRNP formation. Northern blot analyses of extracts from WT and Usb1-depleted 
cells separated in native gels indicated that Usb1 was not involved in U4/U6 di-snRNP and 
U4/U6.U5 tri-snRNP formation, even though their levels were limited by the amount of U6 
(Supplementary Fig. S4A-B).  
We then tested the possibility that Usb1 might be involved in regulation of U6 snRNA 
gene transcription. This hypothesis was examined using chromatin immunoprecipitation 
experiments, which revealed that RNA polymerase occupancy over the U6 snRNA in 
comparison to the control 5S rRNA gene did not change significantly upon Usb1 depletion 
(Supplementary Fig. S5). We next examined U6 snRNA stability in Usb1-depleted cells. 
Half-life analysis via transcription inhibition by thiolutin treatment followed by quantitative 
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northern blot hybridization revealed that the U6 snRNA half-life decreased form 
approximately 10 h to 2.5 h in the absence of Usb1 (Fig. 2 A1-B3 and Supplementary Fig. 
S6A-B). In addition, U6 snRNA degradation products were present upon Usb1 depletion with 
high-resolution northern blot analysis (Fig. 2C, lanes 5 and 6). However, primer extension 
analysis showed no difference at the 5’ end of U6 snRNA (Fig. S6C), suggesting that the 
observed intermediate products resulted from 3' end degradation. These results led us to 
conclude that Usb1 is an U6 snRNA stability factor in yeast.  
USB1 is essential for the  presence of the phosphate moiety at 3'end of U6 snRNA 
Previous studies showed that yeast U6 snRNA is terminated with a single phosphate 
moiety in position 2' or 3' or with hydroxyl groups (Lund and Dahlberg 1992). The presence 
of a phosphate at the 3' (U-P) would be a feature specific to this snRNA, which we wanted to 
analyze in greater detail. In order to determine the properties of the U6 snRNA 3' end, the 
RNA extracted from WT and Usb1-depleted cells was treated with HCl. If there was indeed a 
cyclic phosphate group at this end, HCl treatment would open the cyclic phosphate, which 
could then be removed by Shrimp Alkaline Phosphatase (SAP). RNA extracted from human 
HEK293 cells was used as positive controls of SAP and PNK treatment (Fig. 2D). Treated 
RNA was separated with high-resolution sequencing gels and analyzed with northern blots for 
U6 snRNA. As expected, in WT RNA extracts, the majority of the U6 snRNA molecules 
contained a phosphate moiety at the 2' or 3' end, evident from the slower mobility upon 
treatment with SAP (Fig. 2D1, lanes 1-2) . As expected, HCl treatment had no effect on yeast 
U6 snRNA RNA mobility (Fig. 2D1, lanes 3-4), but resulted in SAP sensitivity of human U6 
snRNA (Fig. 2D2). In contrast to WT, in RNA extracted from USB1 depleted cells, SAP/HCl 
treatment had no effect on U6 snRNA mobility and in general U6 snRNA molecules migrated 
similar to those form WT cells after SAP treatment (Fig. 2D1, compare lanes 1 and 6). In 
order to clarify if U6 snRNA in yeast contains a 2’ or 3’ phosphate at the 3’ end, we 
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performed polynucleotide kinase (PNK) treatment, which is known to have 3’ but not 2’ 
phosphatase activity (Cameron and Uhlenbeck 1977). Our results clearly demonstrate that 
there is a 3’ phosphate moiety at the end of U6 snRNA (Fig. 4E), which is critical for U6 
snRNA stability, and most importantly, that Usb1 is essential for the presence of this 
modification.  
C16orf57/hUSB1 is essential for the presence of the cyclic phosphate at the 3' end of human 
U6 snRNA. 
Having established a role for Usb1 in yeast, we then focused our attention on the 
protein encoded by the human C16orf57, which we named hUSB1. We first asked whether 
hUSB1 is also involved in U6 snRNA 3' end processing in human cells. Using HeLa cells 
transiently transfected with a construct expressing a hUSB1-GFP C-terminal fusion protein, 
we confirmed that hUSB1 was also localized to the nucleus (Fig. 3). We next performed RNA 
interference experiments in HeLa cells using three different small interfering RNAs (siRNAs) 
to examine the effect of knocking down hUSB1 on U6 snRNA. The siRNAs exhibited similar 
silencing efficiencies, as verified by reverse transcription and quantitative PCR 
(Supplementary Fig. S7B). We used high-resolution sequencing gels and northern blot 
analysis combined with HCl/SAP treatments to analyze the effect of siRNA-mediated 
knockdown on U6 snRNA. Upon hUSB1 knockdown, U6 snRNA levels did not change; 
however, U6 snRNA molecules became extended and more heterogeneous in length 
compared to control cells (Fig. 4A). The effect of all 3 different siRNAs has similar kinetic 
(Fig4 B1 and B2) but the effect of siRNA1 on U6 snRNA was the most pronounced.  Our 
experiment also confirmed the presence of 2',3'-cyclic phosphate at the 3' end of human U6 
snRNA (Fig. 4A); however, due to the U6 snRNA molecule heterogeneity in hUSB1-depleted 
cells, it was difficult to draw a clear conclusion about the effect of depletion on the U6 
snRNA 3' end phosphorylation. Heterogeneity of the U6 snRNA after hUSB1 depletion was 
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also confirmed by circularized RNA reverse-transcription PCR (CR-RT-PCR) analysis and 
sequencing the 3' ends of U6 snRNA molecules (Fig. 4C). In addition, in vitro labeling of 
endogenous U6 snRNA by incubation of HeLa nuclear extracts with α-P32-UTP under 
conditions where the U6 snRNA would be the major labeled species revealed that native U6 
snRNA molecules were longer upon hUSB1 depletion (Fig. 4D). 
Subsequently, we determined the phosphorylation status of the 3' ends of U6 snRNA 
after hUSB1 depletion using northern blot experiments. U6 snRNA was purified and ligated 
to pre-adenylated oligonucleotides using either 3' OH-dependent T4 RNA ligase 2 or 2',3'-
cyclic phosphate-dependent tRNA ligase to determine the ratio of U6 snRNA containing a 3' 
cyclic phosphate. In control HeLa cells, the U6 snRNA molecules contained U>P at their 3' 
ends. In contrast, the level of U>P-containing molecules was reduced in the siRNA-treated 
cells. This finding correlated with the accumulation of U6 snRNA molecules extended with a 
3' OH group in Figures 4E and F and Supplementary Figure S8. Accumulation of U6 snRNA 
molecules with 3’OH groups was confirmed for HeLa cell treatment with two additional 
siRNAs against hUSB1 (Fig. 4G). Our results indicate that the presence of 2',3'-cyclic 
phosphate at the U6 snRNA 3' end is dependent on hUSB1, suggesting that, as in yeast, this 
protein is involved in U6 snRNA biogenesis in human cells. 
In order to further understand the role of hUSB1 in U6 snRNA regulation, we 
analyzed the relationship between hUSB1 and other enzymes that are thought to participate in 
U6 snRNA 3' end processing (Fig. 4H and S7A). To this end, we first performed RNA-3'-
phosphate cyclase (RTCD1) knockdowns in HeLa cells. RTCD1 was suggested to be 
involved in U6 3' phosphate cyclization (Genschik et al. 1997); however, we did not observe 
any effects on the U6 3' end upon siRNA-mediated RTCD1 knockdown as judged by northern 
blots analyses of HCl/SAP treated cell extracts (Fig. 4H, lanes 13-16). We next knocked 
down U6 snRNA-specific poly(U) polymerase (TUTase), which significantly reduced the 
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accumulation of extended U6 snRNA molecules, especially in cells with concurrent hUSB1 
knockdown (Fig 4H, compare lane 5 with lanes 1 and 17).  
In the Northern blot analyses, we always observed U6 snRNA molecules that were 
shorter than the major mature species (see Fig 4H, lane 1 as an example). To determine if 
these shorter species are decay intermediates or precursors prior to TUTase-mediated 
extension, we combined hUsb1 and double hUSB1/TUT1 siRNA-mediated knockdown with 
actinomycin-D transcription inhibitor treatment. Northern blot analysis revealed that the 
shorter species disappeared after 2 h of actinomycin-D treatment, strongly suggesting that 
these shorter molecules were precursors (Fig. 4I, lanes 2, 4, and 6). Moreover, actinomycin-D 
treatment led to accumulation of the extended species in hUSB1-depleted cells, which were 
reduced in the hUSB1/TUTase double knockdown (Fig. 4I, compare lanes 2 and 4). Here we 
present the first siRNA-based evidence that TUT1 is indeed responsible for U6 snRNA 3' 
uridylation. However, TUTase does not seem to be directly involved in the formation of the 
cyclic phosphate at the end of U6 snRNA (Fig. 4H, lanes 5-8). 
 To further characterize the effect of hUSB1 knockdown on U6 snRNA, we measured 
the half-life of U6 snRNA in control and siRNA-treated cells. Newly synthesized RNA was 
metabolically labeled by 4-thiouridine (4sU) incorporation (Dolken et al. 2008). RNA isolated 
from the cells was biotinylated in 4-thiouridine specific reaction and then purified using 
streptavidin beads to separate newly-synthesized RNAs from pre-existing RNA fractions (Fig. 
5A-B). The ratio between pre-existing and newly synthesized U6 snRNA was used to 
calculate the half-life of the transcript. In contrast to what we observed in yeast, the stability 
of U6 snRNA was only mildly affected by the lack of 3' modifications, its half-life reducing 
from 15 h to 11 h. This may reflect differences in U6 biogenesis in humans and yeast, for in 
humans U6 TUTase can add uridines to U6 snRNA 3' ends to repair molecules and prevent 
their rapid degradation. Furthermore, the lack of hUSB1 only slightly affected splicing 
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activity of nuclear extracts, which is in agreement with our findings in Figure 5A and B, 
confirming a difference between U6 snRNA biogenesis in yeast and human cells (Fig. 5C). 
USB1 encodes a putative phosphodiesterase which potential catalytic activity is essential for 
its function  
Our results prompted us to carefully examine the Usb1 protein sequence as well as its 
orthologs. PSI-Blast (Altschul et al. 1997) searches initiated with the Usb1 and hUSB1 
sequences identified nearly 200 uncharacterized homologs from all major eukaryotic phyla. 
These searches, however, did not reveal any detectable sequence similarity to any other 
proteins of known structure or function. Using highly-sensitive methods for distant homology 
detection (Ginalski et al. 2004) and fold recognition (Ginalski et al. 2003), we mapped Usb1 
and hUSB1 to various 2H phosphodiesterase structures, including that of a cyclic nucleotide 
phosphodiesterase, 1FSI (Hofmann et al. 2000) and a 2'-5' RNA ligase, 2FYH (Kanai et al. 
2009). Interestingly, hUSB1 was previously classified as a 2H phosphodiesterase superfamily 
member (CG16790-like family of eukaryotic ligT ligases) (Mazumder et al. 2002). In 
addition, a recent theoretical publication also identified hUSB1 as a putative 
phosphodiesterase, but since its molecular function was not determined, hUSB1 was instead 
suggested to be an RNA ligase (Colombo et al. 2012 ). 
To analyze the sequence and structure features of Usb1/hUSB1, we generated multiple 
sequence alignments of USB1 family proteins and selected structures of 2H superfamily 
members and constructed their 3D homology models of Usb1 and hUSB1 (Fig. 6A-B). 
Although one of the hallmarks of the 2H superfamily is its extreme sequence diversity 
(Mazumder et al. 2002), we were able to identify structural and sequence motifs that are 
common to all superfamily members in Usb1 and hUSB1. Similar to other 2H 
phosphodiesterases, our 3D models had two closely interacting and topologically equivalent 
repeats (lobes) with a pseudo two-fold rotational symmetry (Sakamoto et al. 2005). Each lobe 
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consisted of a four stranded, antiparallel beta-sheet flanked by two helices on one side that 
provides a conserved HXT/S catalytic motif within a V-shaped active site cleft (Fig. 6A). 
According to the model, the hUSB1 family members conserved all amino acids critical for the 
enzymatic activity of 2H phosphodiesterases, including the invariant catalytic residues from 
two HXT/S motifs: H120, S122, H208, and S210 (numbered according to hUSB1, Fig. 6C). 
In order to check whether or not putative phosphodiesterase activity is essential for Usb1 
function, we introduced a mutant with putative catalytic residues that were replaced by 
alanines (H133A, H231A) into the GAL::USB1 strain. We found that the mutant Usb1 could 
not restore yeast growth in repressive glucose-rich media, indicating the putative catalytic 
activity of Usb1 is necessary for its essential function in yeast (Fig. 6D). We then preformed 
rescue experiments in human HEK293 stable cell lines where we complemented the effect of 
RNAi by expression of siRNA insensitive WT and H208A mutant hUSB1 constructs. High 
resolution northern blot analysis clearly show that expression of the WT RNAi insensitive 
construct largely rescued the phenotype (Fig.6E   lane 5 and 17), while expression of the 
catalytic mutant did not, and if anything had a slight negative effect (Fig.6E, compare lane 5 
with 6 and 17 with 18). These results indicated that the effect of siRNA treatment on U6 
snRNA is dependent on depletion of hUSB1 and that putative catalytic activity is essential for 
its function. 
Electrostatic surface potential is one of the main factors that may help to distinguish 
between different substrates of 2H phosphodiesterase enzymes (Sakamoto et al. 2005). As 
seen in Supplementary Figure S10, various 2H phosphodiesterases retain specific features of 
their electrostatic surface potential in order to bind molecules of different physicochemical 
properties. As observed by Kato et al. (Kato et al. 2003), an extensive positively charged 
region is essential for the recognition of large negatively charged molecules like RNA. For 
example, 2'-5' tRNA ligase has positively charged regions on both sides of the active site 
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cleft, encompassing its terminal and transit lobes, which allows it to correctly bind both 3’and 
5’ tRNA half molecules. In contrast, plant CPDase and cyclic CMP phosphodiesterase lack 
positive charges around their active site regions, as they are involved in metabolizing small 
molecules, such as ADP-ribose 1",2"-cyclic phosphate (Appr>p) (Supplementary Fig. S10; 
Hofmann et al. 2000). As shown in Figure 6B, hUSB1 has a positively charged region only on 
the terminal lobe. This suggests that hUSB1 is involved in metabolizing a terminal fragment 
of the RNA molecule, such as the poly(U) chain of U6 snRNA. 
In the reaction mechanism proposed for 2H phosphodiesterases (Supplementary Fig. 
S9A-B), serines or threonines are necessary to stabilize the position of a cyclic phosphate 
moiety within the active site, while histidines are responsible for activating a nucleophile and 
the formation of reaction intermediates. Interestingly, a similar overall active site shape with 
two catalytic histidines is observed in the evolutionarily unrelated RNase A (Aravind and 
Koonin 2001). Furthermore, RNase A not only cleaves the RNA P-O5' bond (leading to the 
formation of a cyclic phosphate), but also hydrolyzes a cyclic phosphate moiety using a 
mechanism strikingly similar to that of 2H phosphodiesterases (Supplementary Fig. S9C-D; 
Raines 1998; Cuchillo et al. 2011). Consequently, we propose that hUSB1 catalyzes the 
cleavage of the P-O5' bond at the 3' end of poly(U), resulting in the formation of a 2',3'-cyclic 
phosphate and the removal of the terminal uridine via a mechanism similar to that of RNase A 
(Fig. 6F and Fig. S9D).  
 
Discussion 
In this study, we identified a putative phosphodiesterase which is essential for the U6 
snRNA 3' end processing. We propose that the Usb1 protein is a phosphodiesterase acting as 
an RNase responsible for trimming the poly(U) tract of the last nucleotides in the pre-U6 
snRNA molecule. This leads to the formation of mature U6 snRNA 3'end terminated with a 3' 
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phosphate in yeast or a 2',3'-cyclic phosphate in humans. However, since we did not show the 
activity directly, we cannot formally rule out the possibility that Usb1/hUSB1 is not involved 
in generation, but rather the maintenance of 3/2’,3’-cyclic phosphate or biogenesis of the 
actual enzyme responsible for generation of U6 snRNA 3/2’,3’-cyclic phosphate. However, 
such possibilities seems unlikely. 
Moreover, we showed that, in yeast, the presence of a phosphate at the 3' end of U6 
snRNA is essential for its stability, but not for its successful incorporation into snRNPs. In 
contrast to yeast, the knockdown of hUSB1 in human cells does not lead to significant 
changes in the U6 snRNA half-life. We propose that this difference is due to activity of the 
U6-specific poly(U) polymerase, which can constantly extend shortened U6 snRNA 
molecules. Therefore, the major phenotype of hUSB1 dysfunction is the appearance of 
extended U6 snRNA species in human cells. The sensing mechanism that ensures the proper 
length of oligouridine tract at the 3’ end of human U6 snRNA must exist. Our results do not 
allow for us to provide a molecular description of such phenomenon, but formation of cyclic 
phosphate is crucial for this occurrence, since depletion of hUSB1 leads to accumulation of 
extended species. The majority of U6 snRNA molecules in humans have 4 uridines that may 
correspond to the region protected by LSM proteins.  
Previously, it was suggested that the U6 snRNA 3' end modification is essential for the 
exchange between La RNA chaperone and doughnut-shaped heteromer of seven human Sm-
like proteins (Lsm2-8), as well as for the incorporation of U6 snRNA into larger snRNP 
assemblies (Seraphin 1995; Achsel et al. 1999). However, our results suggest otherwise; we 
showed that splicing efficiency did not change significantly upon hUSB1 knockdown in 
human cells while the over-expression of U6 snRNA restored growth in Usb1-depleted yeast 
cells. Moreover, it seems very unlikely that a dysfunctional exchange between La and LSM 
proteins would lead to yeast U6 snRNA destabilization, since La protein recognizes and, as a 
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result, protects the 3' end of target RNAs. Therefore, we propose that the 3' end modification 
itself has a protective role for U6 snRNA. In fact, the lack of hUSB1 leads to human diseases 
that are severe, yet not lethal, arguing that the U6 snRNA modification is not essential for 
splicing. Moreover, our preliminary analysis of deep RNA sequencing of RNA samples 
isolated from hUSB1-depleted HeLa cells does not show a significant accumulation of 
unspliced introns (data not shown). This suggest that the lack of the U6 snRNA cyclic 
phosphate does not affect global splicing efficiency and that the diseases caused by hUSB1 
mutations may result from subtle differences in splicing. 
It is intriguing why U6 snRNA in yeast is terminated with a 3' phosphate, while in 
humans, with a 2',3' cyclic phosphate. One of the possible explanations is a difference in 
catalytic properties of Usb1 and hUSB1. Unfortunately, our intensive efforts to recapitulate 
the reactions catalyzed by these enzymes in vitro have been unsuccessful to date. Another 
explanation for the difference is that a terminal phosphate cyclase catalyzes cyclization in 
human cells, while the Usb1 leaves a 3' terminal phosphate in yeast cells. However, our 
results showed that the depletion of an obvious candidate for U6 snRNA cyclase RTCD1 did 
not influence the U6 snRNA 3' end formation (Tanaka and Shuman 2009). Conversely, it is 
possible that there is a yeast-specific enzyme that resolves the cyclic phosphate bond, but 
there are no known candidates with such an activity. 
Interestingly, although hUSB1 is localized to the nucleus, which is compatible with its 
proposed enzymatic activity, the yeast ortholog exhibits nuclear and mitochondrial 
localization (Glatigny et al. 2011). Furthermore, Usb1 overexpression was shown to be able 
to compensate for specific respiratory defects of an oxa1 yeast mutant, which suggests that 
Usb1 may be involved in mitochondrial metabolism. However, Usb1’s respiratory function 
was not required for yeast viability, indicating that the growth defects we observed in Usb1-
depleted yeast cells was not due to its function in the mitochondria (Glatigny et al. 2011). 
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Therefore, U6 snRNA 3' end formation might be the main and essential cellular function of 
Usb1. It is important to note that hUsb1 does not localize to the nucleolus, suggesting that the 
3' end processing takes place in the nucleoplasm before the RNA transiently passes into the 
nucleolus, where it is subjected to other post-transcriptional modifications, such as snoRNA-
guided 2'-O-methylation and pseudouridydylation (Kiss 2004). 
Our studies show that Usb1 is a monomer; however, previous studies have reported 
that Usb1 may possibly interact with some proteins involved in the formation of catalytically 
active spliceosome complexes, such as Prp19, Syf1, and Cus2 (Brow 2002; Gavin et al. 
2006). These high throughput studies have certain limitations; however, the proposed 
interactions further support our hypothesis that Usb1 interacts with U6 snRNA. U6 snRNA 3' 
end formation might be synchronized with the early steps of U6 snRNP assembly before it 
enters the nucleolus. Additionally, analysis of the electrostatic surface potential of Usb1 and 
hUsb1 suggests that its terminal lobe has the ability to bind negatively-charged RNA 
molecules. Indeed, Usb1 was detected in a high throughput screen as an RNA-binding protein 
(Scherrer et al. 2010). 
Finally, our results strongly suggest that U6 TUTtase plays a role in the uridylation of 
U6 snRNA precursors. The human U6 TUTase was independently identified as a poly(A) 
polymerase (Star-PAP), which polyadenylates a subset of mRNAs in the nucleus and is 
regulated by phosphatidylinositol 4,5-bisphosphate (Mellman et al. 2008). The authors of this 
study also questioned the function of the U6 TUTase in U6 snRNA metabolism. It would be 
very intriguing if U6 TUTtase is indeed a dual function protein, also serving as a poly(A) 
polymerase. 
In summary, we identified a putative U6 snRNA phosphodiesterase as a first step 
toward understanding the biological mechanism of poikiloderma-neutropenia, dyskeratosis 
congenita and Rothmund-Thomson syndrome, in which hUSB1 is mutated. Further research 
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is however needed to understand biological and medical consequences of the lack of cyclic 
phosphate at the 3’ end of U6 snRNA. 
 
Materials and Methods 
Strain and plasmid construction 
Yeast strains, plasmids, oligonucleotides, and siRNAs used in this study are listed in 
Supplementary Tables 2, 3, 4, and 5. Yeast strains were transformed as previously described 
(Gietz et al. 1992). The GAL::USB1 and HA-C160/GAL::USB1 strains were constructed by 
homologous recombination of a cassette amplified by PCR using the USB1GALF and 
USB1GALR primers from pFA6-kanMX6-PGAL1 to the WT or MW671-HA strain 
genomes, respectively. Clones were verified by PCR with USB1verF and USB1verR primers. 
Other strains were prepared by transformation with the appropriate plasmids. Standard yeast 
genetic methods and selective growth media were used as previously described (Guthrie C, 
Fink GR. (eds) 1991). 
The plasmids pRS415-USB1H133A and pRS415-USB1H231A were obtained by site-
directed mutagenesis using the USB133F/USB133R and USB231F/USB231R primers, 
respectively, with the pRS415-USB1 plasmid serving as a template. Mutations were 
confirmed by sequencing.  
tRNA ligase (AT1G07910.1) construct for recombinant protein production in 
Escherichia coli was papered by PCR amplification from A. thaliana cDNA using 
pET28AtLigF and pET28AtLigR primers. The PCR product was subsequently cloned into a 
modified pET28 vector using the SLIC method (Li and Elledge 2007). 
The pcDNA-hUSB1GFP construct was prepared by PCR amplification from human 
cDNA using pcDNAhUSB1F and pcDNAhUSB1R primers. The PCR product was 
subsequently cloned into a modified version of the pcDNA™5/FRT/TO vector (Invitrogen). 
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The details of this method will be published in a forthcoming publication. Plasmids encoding 
hUSB1 carrying silent mutations in sequences complementary to siRNA and H208A mutation   
were obtained by site-directed mutagenesis of pcDNA-hUSB1GFP plasmid resulting in 
:pcDNA-hUSB1si1Rec (hUSB1 WT siRNA1 insensitive) (oligonucleotides: hUSB1si1RecF, 
hUSB1si1RecR), pcDNA-hUSB1si1Rec H208A (hUSB1 H208A mutant siRNA1 insensitive) 
(oligonucleotides: hUSB1si1RecF, hUSB1si1RecR and hUSB1H208AF, hUSB1H208AR)  
and pcDNA-hUSB1GFP H208A (hUSB1 H208A siRNA1 sensitive) (oligonucleotides: 
hUSB1H208AF, hUSB1H208AR). 
Cultures 
Yeast strains were pre-grown in YPGAL medium  (1% yeast extract, 2% peptone, 2% 
galactose) at 30 °C and switched to YPD medium (1% yeast extract, 2% peptone, 2% 
glucose) during logarithmic growth phase. For the depletions performed over a long time 
period, growth was monitored throughout the entire experiment and the cultures were 
maintained in logarithmic phase. Thiolutin (T3450, Sigma) was added to the yeast culture at a 
final concentration of 3 or 15 µg/mL. The cells were treated for up to 4 h and samples were 
taken at different times over the course of the culture. 
HeLa and HEK293 T-Rex FLP-in (Invitrogen) cells were cultured in monolayers in 
DMEM (Gibco) supplemented with 10% FBS (Gibco) or TET System Approved FBS 
(Clontech) in case of stable, inducible cell lines at 37 °C in a 5% CO2 humidified atmosphere. 
Actinomycin-D (Sigma) was added at a final concentration of 5 µg/mL for 2 h. Stably 
ternsfected HEK293 T-Rex FLP-in cell lines were selected according to the manufacturer’s 
suggestions (Invitrogen). Expression of exogenous genes was induced by addition of 
tetracycline to the culture medium at a concentration of 25 ng/ml 
 
Yeast genetic screen 
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The GAL::USB1 strain was transformed with the Saccharomyces cerevisiae AB320 
pYEp13 genomic library (37323, ATCC) and plated onto synthetic complete medium (SC, 
0.67% yeast nitrogen base, 2% glucose) without leucine to maintain the plasmid. After 3 days 
the colonies were replica-plated onto YPGAL and YPD plates and grown for an additional 3 
days at 30°C. Plasmids from the 30 positive clones growing on restrictive media were isolated 
and sequenced. In order to verify results of the suppressor screen, the GAL:USB1 strain was 
transformed with pYX172-U6 and grown on galactose and glucose media. 
RNA isolation and northern blotting 
Yeast total RNA was isolated using the GTC/phenol method (Alexander et al. 2010). 
Total RNA from HeLa cells was purified with TRIzol according to the manufacturer’s 
instructions (Invitrogen). Northern analyses and primer extension reactions were performed as 
previously described (Mroczek and Kufel 2008). Standard 6% or 8% acrylamide gels were 
used to separate low molecular weight RNAs. High-resolution electrophoresis was performed 
in 6% sequencing gels in 0.5x TBE buffer. 
RNA treatment with HCl, SAP, and PNK  
RNA was incubated in the presence of 100 mM HCl for 4 h on ice and then 
precipitated. The samples were then treated with Shrimp Alkaline Phosphatase (SAP) 
(Fermentas) or T4 Polynucleotide Kinase (PNK) (New England Biolabs) according to the 
manufacturer’s instructions. Finally, RNA was purified with phenol/chloroform extraction.  
In vitro splicing assay with yeast extracts 
Yeast whole-cell extracts were prepared as previously described (Seraphin and 
Rosbash 1989). Pre-mRNA was generated by in vitro transcription of the pBS195 plasmid 
(digested with the DdeI). Splicing reactions were carried out for 30 to 90 min at 30°C and the 
resulting RNA was purified with phenol/chloroform. Reaction products were analyzed in 15% 
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polyacrylamide gels. When necessary, purified native U6 snRNA was added at a final 
concentration of 100 nM. 
Purification of native U6 snRNA from yeast  
Yeast snRNPs were purified from 20 L of yeast culture by affinity chromatography of 
TAP-tagged Prp24 as described in the “Tap purification” section. RNA was purified from 
protein fractions by phenol/chloroform and U6 snRNA was gel-purified. 
RNP and RNA analyses in native gels 
Analyses were performed as previously described (Verdone et al. 2004). The samples 
were fractionated in native gels, then blotted and hybridized with oligonucleotide probes 
against U4, U5 and U6 snRNA. 
TAP purification  
The TAP purifications were performed from 20 L of yeast culture as previously 
(Rigaut et al. 1999) using an Akta FPLC purification system (GE Healthcare). The fractions 
collected were concentrated by pyrogallol red precipitation, separated by SDS-PAGE, and 
stained with Coomassie Blue. 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed as previously described (El 
Hage et al. 2008) using Dynabeads Protein G (Invitrogen, 100-03D) and a α-HA mAb 
(Roche; 12CA5). The precipitated chromatin was amplified in triplicate with Platinum® 
SYBR® Green qPCR SuperMix-UDG (Invitrogen) using a LightCycler LC480 PCR machine 
(Roche). The oligonucleotides used for the quantitative PCRs are listed in Supplementary  
Table 4. The ChIP values for RNA polymerase III occupancy were determined using the 
formula:  
x = 2-(Ct IP U6 snRNA – Ct U6 snRNA background) / 2-(Ct IP 5S rRNA – Ct 5S rRNA background), 
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where Ct IP is the cycle number for the immunoprecipitate and Ct background is the cycle 
number for the control beads without antibody. 
hUSB1 localization  
HeLa Kyoto cells were transfected with 2 µg of DNA using the TransIT 2020 reagent 
(Mirus). Four hours after transfection, the cells were re-plated in dishes with poly-L-lysine 
coated cover glasses. Twenty-four hours after transfection, the cells were stained with 
Hoechst 33342 (Invitrogen) and fixed with formaldehyde. The cover glasses were then 
mounted in Prolon Gold medium (Invitrogen). The cells were imaged with an FV1000 
confocal system (Olympus). 
siRNA transfection 
For the siRNA-mediated knockdown, 6 × 105 HeLa or 2 × 106 HEK293 cells growing 
in 100 mm plates were transfected with 20 nM siRNA (listed in Supplementary Table 5, 
Invitrogen) using 15 μL Lipofectamine RNAiMAX (Invitrogen). Cells were harvested at 48, 
72, or 96 h after transfection. In case of 96 h, cells were replated after 48 h post-transfection. 
Appropriate controls were used as recommended by the manufacturer of the siRNAs. For 
preparation of the nuclear extracts, cells growing in 12 100-mm plates were re-plated 48 h 
after transfection in 12 145-mm plates and cultured for an additional 48 h. Control nuclear 
extracts were prepared from non-transfected cells. 
Determination of mRNA levels after siRNA-mediated gene silencing  
Ten µg total RNA was treated with Turbo DNase (Ambion) according to the 
manufacturer’s instructions. cDNA was prepared using SuperScript III reverse transcriptase 
and oligo (dT)18 primer (Invitrogen). qPCR reactions were performed as described in the 
“Chromatin immunoprecipitation” section. Transcript levels were normalized to that of 
GAPDH. 
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Circularized RNA reverse transcription PCR (CR-RT-PCR) 
The CR-RT-PCR reactions were performed as previously described (Kuhn and Binder 
2002) with some modifications. Briefly, to remove γ-monomethylguanosine triphosphate, 10 
µg total RNA was annealed with oligonucleotide hU6RH and then digested with RNAse H as 
described previously (Decker and Parker 1993). Samples were then treated with 10 U of SAP 
phosphatase (Fermentas) and RNA was purified by phenol/chloroform extraction. RNA was 
circularized using T4 RNA ligase (NEB). The cDNA was prepared using SuperScript III 
Reverse Transcriptase (Invitrogen) with the oligonucleotide U6CRPRT. The U6 ends were 
amplified in a PCR reaction with the oligonucleotides U6CR-F1 and U6CR-R1 and cloned 
using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen). Sequencing was performed using 
the M13 Rev primer. 
Preparation of nuclear extracts from cell lines, in vitro splicing, and RNA labeling  
Small-scale nuclear extracts from siRNA-treated and control HeLa cells were prepared 
as previously described (Kataoka and Dreyfuss 2008). The AdML pre-mRNA splicing 
substrate was transcribed in vitro from the HMS81 plasmid digested with BamHI. The 
splicing reactions were set up as previously described (Le Hir et al. 2000). The reactions were 
conducted for up to 90 min. RNA was extracted with phenol/chloroform and analyzed in 15% 
polyacrylamide gels with 7 M urea. 
To label U6 snRNA, 30 µL of nuclear extract was incubated with 50 µCi of α-32P-
UTP for 60 min at 30 °C. RNA was purified using the GTC/phenol method, precipitated, 
separated on a 6% polyacrylamide gel, and visualized by autoradiography.  
Ligation of L3 adapters to U6 snRNA 3'ends  
Twenty µg total RNA was annealed to 500 pM anti-U6BtnTg oligonucleotide (Sigma) 
in 1x hybridization buffer (250 mM NaCl, 10 mM Tris pH 7.5, 2 mM EDTA pH 8.0) and 
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immobilized on Dynabeads M-280 Streptavidin beads (Invitrogen) according to the 
manufacturer’s instructions. Ligations were performed on the beads using 200 µM L3 linker 
oligonucleotide (IDT DNA) and 200 U T4 RNA Ligase 2 (NEB), or cyclic-phosphate (P>) 
specific Arabidopsis thaliana tRNA ligase (AT1G07910.1) as previously described (Schutz et 
al. 2010). The samples were separated in 6% sequencing gels and analyzed by northern 
blotting using anti-L3 and hU6 probes. 
 
Labeling and purification of nascent RNA  
Four-thiouridine (Sigma) at a concentration of 200 µM was added to the media for 2 
h, after which the cells were harvested and RNA was purified. RNA biotinylation and capture 
steps were performed as described previously (Dolken et al. 2008). Purified RNA was 
separated on 6% polyacrylamide gels, blotted, and hybridized against U6 snRNA and 5S 
rRNA. Densitometric analyses were performed using Multi Gauge software (Fuji). The U6 
snRNA half-life values were calculated according to the following formula: 
t1/2 = -tL × ln2 / ln (1-R), 
where R is the newly transcribed RNA:total RNA ratio, tL is the duration of labeling, and t1/2 
is the RNA half-life (Dolken et al. 2008). 
 Recombinant protein expression and purification 
Arabidopsis thaliana tRNA ligase was expressed in the E. coli BL21-CodonPlus-RIL 
strain (Stratagene) as a N-terminal HIStag-SUMOtag fusion. 
Bioinformatic analyses 
Proteins belonging to the USB1 family were identified with PSI-Blast (Altschul et al. 
1997) searches (E-value threshold = 0.005) performed against the NCBI non-redundant 
protein sequence database using hUSB1/USB1 sequence as a query. Multiple sequence 
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alignment was derived using the PCMA program (Pei et al. 2003) followed by manual 
adjustments. Secondary structures were predicted using PSIPRED (McGuffin et al. 2000). 
Distantly-related proteins of known structure were identified with the meta-profile 
comparison method Meta-BASIC (Ginalski et al. 2004) and consensus of fold recognition 
3D-Jury (Ginalski et al. 2003). Sequence-to-structure alignment between the USB1 family 
and selected structures was built using a consensus alignment approach and 3D assessment 
(Ginalski and Rychlewski 2003) based on the results of Meta-BASIC and 3D-Jury mappings, 
as well as conservation of the critical active site residues, hydrophobic patterns, and 
secondary structure predictions. The 3D models of hUSB1 and USB1 were constructed with 
MODELLER (Fiser and Sali 2003) using the following structures as templates: RNA ligases 
from P. horikoshii (Protein Data Bank [PDB], 1VGJ) and T. thermophilus (PDB, 1IUH; Kato 
et al. 2003) and H. sapiens kinase A anchoring protein (PDB, 2VFK; Gold et al. 2008). 
Electrostatic potential was calculated using the APBS tool (Baker et al. 2001).  
Acknowledgements 
We thank Kasia Kowalska for help with DNA cloning, Krystian Stoduś for 
recombinant protein purification, Aleksander Chlebowski for help with confocal imaging, 
Marta Olchowik from The Laboratory of Cytometry at the Nencki Institute for cell sorting, 
Herve Le Hir for advice on in vitro splicing, and members of the AD and KG laboratories for 
stimulating discussions. We thank Joanna Kufel and Bertrand Seraphin for their critical 
reading of the manuscript. This work was supported by the Ministry of Science and Higher 
Education, EMBO Installation Programme, Foundation for Polish Science Team Programme, 
co-financed by the EU European Regional Development Fund and the Operational Program 
Innovative Economy 2007-2013 (Agreement POIG.02.02.00-14-024/08-00). 
Author contributions 
26 
 
AD and KG conceived and directed the studies. SM performed all of the experiments 
on human cell lines and the majority of experiments in yeast. JKr performed the initial 
experiments shown in Figures 1A, 1C, 6D, and S2. JKu performed the multicopy suppressor 
screen shown in Figure 1B and participated in the initial biochemical experiments shown in 
Supplementary Figure S3. IK participated in the initial experiments in yeast. ML and KG 
performed bioinformatic analyses. AD wrote the manuscript with contributions from SM, 
ML, and KG.  
 
References 
Achsel T, Brahms H, Kastner B, Bachi A, Wilm M, Luhrmann R. 1999. A doughnut-shaped 
heteromer of human Sm-like proteins binds to the 3'-end of U6 snRNA, thereby 
facilitating U4/U6 duplex formation in vitro. EMBO J 18: 5789-5802. 
Alexander RD, Barrass JD, Dichtl B, Kos M, Obtulowicz T, Robert MC, Koper M, 
Karkusiewicz I, Mariconti L, Tollervey D et al. 2010. RiboSys, a high-resolution, 
quantitative approach to measure the in vivo kinetics of pre-mRNA splicing and 3'-
end processing in Saccharomyces cerevisiae. RNA 16: 2570-2580. 
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. 
Gapped BLAST and PSI-BLAST: a new generation of protein database search 
programs. Nucleic Acids Res 25: 3389-3402. 
Aravind L, Koonin EV. 2001. A natural classification of ribonucleases. Methods Enzymol 
341: 3-28. 
Armanios M. 2009. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 10: 
45-61. 
27 
 
Arnold AW, Itin PH, Pigors M, Kohlhase J, Bruckner-Tuderman L, Has C. 2010. 
Poikiloderma with neutropenia: a novel C16orf57 mutation and clinical diagnostic 
criteria. Br J Dermatol 163: 866-869. 
Arnold AW, Itin PH, Pigors M, Kohlhase J, Bruckner-Tuderman L, Has C. 2010. 
Poikiloderma with neutropenia: a novel C16orf57 mutation and clinical diagnostic 
criteria. Br J Dermatol 163: 866-869. 
Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. 2001. Electrostatics of nanosystems: 
application to microtubules and the ribosome. Proc Natl Acad Sci U S A 98: 10037-
10041. 
Brow DA. 2002. Allosteric cascade of spliceosome activation. Annu Rev Genet 36: 333-360. 
Cameron V, Uhlenbeck OC. 1977. 3'-Phosphatase activity in T4 polynucleotide kinase. 
Biochemistry 16: 5120-5126. 
Clericuzio C, Harutyunyan K, Jin W, Erickson RP, Irvine AD, McLean WH, Wen Y, Bagatell 
R, Griffin TA, Shwayder TA et al. 2011. Identification of a novel C16orf57 mutation 
in Athabaskan patients with Poikiloderma with Neutropenia. Am J Med Genet A 
155A: 337-342. 
Colombo EA, Bazan FJ, Negri G, Gervasini C, Elcioglu NH, Yucelten D, Altunay I, 
Cetincelik U, Teti A, Del Fattore A et al. 2012. Novel C16orf57 mutations in patients 
with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and 
predicted effects of all reported mutations. Orphanet J Rare Dis 7: 7. 
Cuchillo CM, Nogues MV, Raines RT. 2011. Bovine pancreatic ribonuclease: fifty years of 
the first enzymatic reaction mechanism. Biochemistry 50: 7835-7841. 
Decker CJ, Parker R. 1993. A turnover pathway for both stable and unstable mRNAs in yeast: 
evidence for a requirement for deadenylation. Genes Dev 7: 1632-1643. 
28 
 
Dolken L, Ruzsics Z, Radle B, Friedel CC, Zimmer R, Mages J, Hoffmann R, Dickinson P, 
Forster T, Ghazal P et al. 2008. High-resolution gene expression profiling for 
simultaneous kinetic parameter analysis of RNA synthesis and decay. RNA 14: 1959-
1972. 
El Hage A, Koper M, Kufel J, Tollervey D. 2008. Efficient termination of transcription by 
RNA polymerase I requires the 5' exonuclease Rat1 in yeast. Genes Dev 22: 1069-
1081. 
Fiser A, Sali A. 2003. Modeller: generation and refinement of homology-based protein 
structure models. Methods Enzymol 374: 461-491. 
Gavin AC, Aloy P, Grandi P, Krause R, Boesche M, Marzioch M, Rau C, Jensen LJ, Bastuck 
S, Dumpelfeld B et al. 2006. Proteome survey reveals modularity of the yeast cell 
machinery. Nature 440: 631-636. 
Gietz D, St Jean A, Woods RA, Schiestl RH. 1992. Improved method for high efficiency 
transformation of intact yeast cells. Nucleic Acids Res 20: 1425. 
Ginalski K, Elofsson A, Fischer D, Rychlewski L. 2003. 3D-Jury: a simple approach to 
improve protein structure predictions. Bioinformatics 19: 1015-1018. 
Ginalski K, Rychlewski L. 2003. Protein structure prediction of CASP5 comparative 
modeling and fold recognition targets using consensus alignment approach and 3D 
assessment. Proteins 53 Suppl 6: 410-417. 
Ginalski K, von Grotthuss M, Grishin NV, Rychlewski L. 2004. Detecting distant homology 
with Meta-BASIC. Nucleic Acids Res 32: W576-581. 
Glatigny A, Mathieu L, Herbert CJ, Dujardin G, Meunier B, Mucchielli-Giorgi MH. 2011. An 
in silico approach combined with in vivo experiments enables the identification of a 
new protein whose overexpression can compensate for specific respiratory defects in 
Saccharomyces cerevisiae. BMC Syst Biol 5: 173. 
29 
 
Gold MG, Smith FD, Scott JD, Barford D. 2008. AKAP18 contains a phosphoesterase 
domain that binds AMP. J Mol Biol 375: 1329-1343. 
Gu J, Shumyatsky G, Makan N, Reddy R. 1997. Formation of 2',3'-cyclic phosphates at the 3' 
end of human U6 small nuclear RNA in vitro. Identification of 2',3'-cyclic phosphates 
at the 3' ends of human signal recognition particle and mitochondrial RNA processing 
RNAs. J Biol Chem 272: 21989-21993. 
Guthrie C, Fink GR. (eds) 1991. Guide to yeast genetics and molecular biology. Methods 
Enzymol 194: 1-863. 
Hofmann A, Zdanov A, Genschik P, Ruvinov S, Filipowicz W, Wlodawer A. 2000. Structure 
and mechanism of activity of the cyclic phosphodiesterase of Appr>p, a product of the 
tRNA splicing reaction. EMBO J 19: 6207-6217. 
Kanai A, Sato A, Fukuda Y, Okada K, Matsuda T, Sakamoto T, Muto Y, Yokoyama S, 
Kawai G, Tomita M. 2009. Characterization of a heat-stable enzyme possessing GTP-
dependent RNA ligase activity from a hyperthermophilic archaeon, Pyrococcus 
furiosus. RNA 15: 420-431. 
Kandels-Lewis S, Seraphin B. 1993. Involvement of U6 snRNA in 5' splice site selection. 
Science 262: 2035-2039. 
Kataoka N, Dreyfuss G. 2008. Preparation of efficient splicing extracts from whole cells, 
nuclei, and cytoplasmic fractions. Methods Mol Biol 488: 357-365. 
Kato M, Shirouzu M, Terada T, Yamaguchi H, Murayama K, Sakai H, Kuramitsu S, 
Yokoyama S. 2003. Crystal structure of the 2'-5' RNA ligase from Thermus 
thermophilus HB8. J Mol Biol 329: 903-911. 
Kiss T. 2004. Biogenesis of small nuclear RNPs. J Cell Sci 117: 5949-5951. 
Kuhn J, Binder S. 2002. RT-PCR analysis of 5' to 3'-end-ligated mRNAs identifies the 
extremities of cox2 transcripts in pea mitochondria. Nucleic Acids Res 30: 439-446. 
30 
 
Larizza L, Roversi G, Volpi L. 2010. Rothmund-Thomson syndrome. Orphanet J Rare Dis 5: 
2. 
Le Hir H, Izaurralde E, Maquat LE, Moore MJ. 2000. The spliceosome deposits multiple 
proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J 19: 
6860-6869. 
Lesser CF, Guthrie C. 1993. Mutations in U6 snRNA that alter splice site specificity: 
implications for the active site. Science 262: 1982-1988. 
Li MZ, Elledge SJ. 2007. Harnessing homologous recombination in vitro to generate 
recombinant DNA via SLIC. Nat Methods 4: 251-256. 
Lund E, Dahlberg JE. 1992. Cyclic 2',3'-phosphates and nontemplated nucleotides at the 3' 
end of spliceosomal U6 small nuclear RNA's. Science 255: 327-330. 
Mazumder R, Iyer LM, Vasudevan S, Aravind L. 2002. Detection of novel members, 
structure-function analysis and evolutionary classification of the 2H phosphoesterase 
superfamily. Nucleic Acids Res 30: 5229-5243. 
McGuffin LJ, Bryson K, Jones DT. 2000. The PSIPRED protein structure prediction server. 
Bioinformatics 16: 404-405. 
Mellman DL, Gonzales ML, Song C, Barlow CA, Wang P, Kendziorski C, Anderson RA. 
2008. A PtdIns4,5P2-regulated nuclear poly(A) polymerase controls expression of 
select mRNAs. Nature 451: 1013-1017. 
Mroczek S, Kufel J. 2008. Apoptotic signals induce specific degradation of ribosomal RNA 
in yeast. Nucleic Acids Res 36: 2874-2888. 
Pannone BK, Kim SD, Noe DA, Wolin SL. 2001. Multiple functional interactions between 
components of the Lsm2-Lsm8 complex, U6 snRNA, and the yeast La protein. 
Genetics 158: 187-196. 
31 
 
Patel SB, Bellini M. 2008. The assembly of a spliceosomal small nuclear ribonucleoprotein 
particle. Nucleic Acids Res 36: 6482-6493. 
Pei J, Sadreyev R, Grishin NV. 2003. PCMA: fast and accurate multiple sequence alignment 
based on profile consistency. Bioinformatics 19: 427-428. 
Piard J, Holder-Espinasse M, Aral B, Gigot N, Rio M, Tardieu M, Puzenat E, Goldenberg A, 
Toutain A, Franques J et al. 2011. Systematic search for neutropenia should be part of 
the first screening in patients with poikiloderma. Eur J Med Genet. 
Raines RT. 1998. Ribonuclease A. Chem Rev 98: 1045-1066. 
Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, Seraphin B. 1999. A generic protein 
purification method for protein complex characterization and proteome exploration. 
Nat Biotechnol 17: 1030-1032. 
Sakamoto Y, Tanaka N, Ichimiya T, Kurihara T, Nakamura KT. 2005. Crystal structure of the 
catalytic fragment of human brain 2',3'-cyclic-nucleotide 3'-phosphodiesterase. J Mol 
Biol 346: 789-800. 
Scherrer T, Mittal N, Janga SC, Gerber AP. 2010. A screen for RNA-binding proteins in yeast 
indicates dual functions for many enzymes. PLoS One 5: e15499. 
Schutz K, Hesselberth JR, Fields S. 2010. Capture and sequence analysis of RNAs with 
terminal 2',3'-cyclic phosphates. RNA 16: 621-631. 
Seraphin B. 1995. Sm and Sm-like proteins belong to a large family: identification of proteins 
of the U6 as well as the U1, U2, U4 and U5 snRNPs. EMBO J 14: 2089-2098. 
Seraphin B, Rosbash M. 1989. Identification of functional U1 snRNA-pre-mRNA complexes 
committed to spliceosome assembly and splicing. Cell 59: 349-358. 
Tanaka A, Morice-Picard F, Lacombe D, Nagy N, Hide M, Taieb A, McGrath J. 2010. 
Identification of a homozygous deletion mutation in C16orf57 in a family with 
Clericuzio-type poikiloderma with neutropenia. Am J Med Genet A 152A: 1347-1348. 
32 
 
Tanaka N, Shuman S. 2009. Structure-activity relationships in human RNA 3'-phosphate 
cyclase. RNA 15: 1865-1874. 
Tazi J, Forne T, Jeanteur P, Cathala G, Brunel C. 1993. Mammalian U6 small nuclear RNA 
undergoes 3' end modifications within the spliceosome. Mol Cell Biol 13: 1641-1650. 
Trippe R, Guschina E, Hossbach M, Urlaub H, Luhrmann R, Benecke BJ. 2006. 
Identification, cloning, and functional analysis of the human U6 snRNA-specific 
terminal uridylyl transferase. RNA 12: 1494-1504. 
Trippe R, Richly H, Benecke BJ. 2003. Biochemical characterization of a U6 small nuclear 
RNA-specific terminal uridylyltransferase. Eur J Biochem 270: 971-980. 
Valadkhan S. 2010. Role of the snRNAs in spliceosomal active site. RNA Biol 7: 345-353. 
Verdone L, Galardi S, Page D, Beggs JD. 2004. Lsm proteins promote regeneration of pre-
mRNA splicing activity. Curr Biol 14: 1487-1491. 
Volpi L, Roversi G, Colombo EA, Leijsten N, Concolino D, Calabria A, Mencarelli MA, 
Fimiani M, Macciardi F, Pfundt R et al. 2010. Targeted next-generation sequencing 
appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene. Am J Hum 
Genet 86: 72-76. 
Wahl MC, Will CL, Luhrmann R. 2009. The spliceosome: design principles of a dynamic 
RNP machine. Cell 136: 701-718. 
Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. 2010. Mutations in C16orf57 and 
normal-length telomeres unify a subset of patients with dyskeratosis congenita, 
poikiloderma with neutropenia and Rothmund-Thomson syndrome. Hum Mol Genet 
19: 4453-4461. 
 
 
  
33 
 
 
Figure legends 
Figure 1. Usb1 depletion leads to splicing defects caused by a reduction in U6 snRNA 
levels. (A) Usb1 depletion causes growth arrest in yeast. Growth curves of wild type (WT) 
and the GAL::USB1 strain (with the USB1 gene under the control of a galactose-inducible 
promoter) cultured on permissive YPGAL and repressive YPD media. The presented values 
were corrected for dilution and are shown as log OD600, where t is the time in hours.  
(B) U6 snRNA overexpression suppresses the growth arrest caused by Usb1 depletion. The 
expression of additional copies of U6 snRNA or USB1 fully restores growth of the 
GAL::USB1 strain on glucose-rich repressive media (YPD). (C) Depletion of Usb1 leads to in 
vivo splicing defects and the accumulation of precursor RNAs, which is correlated with 
reduced levels of U6 snRNA. Northern blot analysis for U1, U2, U6 snRNAs, and precursor 
and mature U3 snRNA is shown. Total RNA was isolated from WT and GAL::USB1 strains 
grown in repressive YPD media for up to 18 h. All hybridizations were performed with the 
same blot. (D) Extracts lacking Usb1 have reduced splicing activity in vitro, a defect that is 
partially restored by addition of U6 snRNA isolated from a TAP-purified Prp24 fraction to 
the splicing reaction. Splicing reactions were performed using extracts prepared from WT 
(lanes 1-4) or GAL::USB1 cells after 8 (lanes 5-12), 10 (lanes 13-20), and 12 h (lanes 21-28) 
of Usb1 depletion. Reactions were carried out for 0, 30, 60, and 90 min. Reaction products 
were fractionated in 15% polyacrylamide gels and detected by autoradiography. The cell 
extracts were supplemented with U6 snRNA in order to resume splicing activity. (E) 
Quantifications of the in vitro splicing reaction product and its intermediates. The graph 
shows relative levels of mature RP51a mRNA and its splicing intermediates: intron-lariat 
(IVS), intron-exon2 (IVS-E2), and exon1 (E1) in splicing reactions performed using extracts 
from WT and GAL::USB1 strain after 8 h of Usb1 depletion. All values are averages from 
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three independent splicing reactions. Autoradiograms were quantified using MultiGauge 
software. 
Figure 2. Depletion of Usb1 reduces U6 snRNA half-life and leads to accumulation of 
decay intermediates. (A, B) The GAL::USB1 strain was grown in permissive YPGAL media 
(A1) or repressive YPD media for 8 h (A2). The WT strain was grown on YPD (B1), YPGAL 
(B2), or pre-grown on YPGAL media and shifted to YPD for 8 h (B3). Cells were treated with 
the RNA polymerase inhibitor thiolutin, then total RNA was extracted at indicated times for 
northern blot hybridizations against U6 snRNA, 5.8S rRNA as the loading control, and 
tRNALeu (CAA) precursor as the thiolutin treatment indicator. Depletion of Usb1 led to U6 
snRNA instability and decreased half-life from 10 h to 2.5 h (compare A2, lanes 7-11 to A1, 
lanes 7-11). For additional quantification analyses, please see the supplementary data 
(Supplementary Fig. S6A-B). (C) High-resolution northern blot analysis of RNA from 
GAL::USB1 + pU6 and GAL::USB1 growing in permissive YPGAL (lanes 1-3 and 7-9, 
respectively) or repressive YPD media (lanes 4-6 and 10-12, respectively) and treated with 
thiolutin for 4 h. The degradation products of U6 snRNA were detectable in the samples after 
48 h of depletion (lanes 5, 6). Long periods of Usb1 depletion caused changes in the 
migration of U6 snRNA (lanes 1 and 4).  
(D1) Analysis of U6 snRNA 3’ termini after Usb1 depletion. Total RNA from WT (lanes 1-4) 
and GAL::USB1 + pU6 (lanes 5-8) growing in repressive YPD media for 48 h was treated 
with HCl and/or shrimp alkaline phosphatase (SAP) and analyzed by northern blotting. Only 
the U6 snRNA isolated from WT cells changed its migration toward the longer species upon 
phosphate removal by SAP, whereas HCl treatment, which can open the cyclic phosphate 
ring, had no effect on migration. (D2) Total RNA from HEK293 cells was treated with SAP 
and HCl similar to that for yeast, and U6 snRNA was detected by high resolution northern 
blot . 
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 (E) The U6 snRNA is terminated with 3’ phosphate at 3’end. Total RNA from GAL::USB1 
grown on YPGAL (lanes 1-4) and WT cultured on YPD (lanes 5-8) was treated with T4 PNK 
kinase (lanes 3 and 7) or SAP (lanes 1 and 5) as control.  
 
Figure 3. hUSB1 is a nuclear protein. HeLa cells were transiently transfected with a 
plasmid bearing a hUSB1-GFP fusion gene. Twenty-four hours after transfection, cells were 
examined by confocal microscopy. The fluorescence images for GFP and Hoechst nucleic 
acid stain, a differential interference contrast (DIC) image, and a merged image are presented 
for hUSB1GFP and the negative control. 
Figure 4. hUSB1 is essential for the presence of the cyclic phosphate at the U6 snRNA 3' 
end. (A) U6 snRNA molecules are more heterogeneous and elongated after hUSB1 depletion 
by RNAi. High-resolution northern blot analysis of RNA from control (lanes 1-4) and siRNA-
treated (lanes 5-16) HeLa cells are shown. In order to examine the phosphorylation status, 
RNA was treated with HCl and/or SAP phosphatase, which in control cells led to a shift in U6 
snRNA on the gel caused by cyclic phosphate removal. (B) Kinetics of the effect of three 
siRNAs against hUsb1 on the U6 snRNA. The HEK293 cells were treated with three siRNAs 
against hUSB1 and then harvested at the indicated time points. Total RNA was analyzed with 
high-resolution northern blots (B1). The U6 snRNA molecules were quantified with 
MultiGauge software and shown as 3-dimentional plot (B2).  
(C) U6 snRNA molecules are more heterogeneous at the 3' end upon hUSB1 depletion. 
Circularized RNA reverse transcription PCR (CR-RT-PCR) analysis of U6 snRNA from 
control and siRNA-treated HeLa cells is shown. Before ligation, the RNA was treated with 
HCl and SAP in order to remove the phosphate moiety from the 3' end. RNase H cleavage 
was performed in order to remove the γ-monomethylguanosine triphosphate (meGTP) 
structure from the U6 5' end. After reverse transcription and PCR, the reaction products were 
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cloned and sequenced. This confirmed increased heterogeneity at the 3' ends of U6 snRNA 
molecules after siRNA treatment. The numbers indicate the amount of independent clones 
that were sequenced. (D) RNA labeling in nuclear extracts confirms the changes in U6 
snRNA mobility in high-resolution gels. Native U6 snRNA was labeled by incubating nuclear 
extracts from control (lane 1) or siRNA-treated (lane 2) HeLa cells with α-32P-UTP. Isolated 
RNA was separated on 6% sequencing polyacrylamide gels and detected by autoradiography. 
(E-G) The formation of the U6 snRNA cyclic phosphate moiety is hUSB1 dependent. U6 
snRNA from control (E, lanes 1, 3, and 5) and siRNA-treated (E, lanes 2, 4, and 6) cells was 
captured with streptavidin magnetic beads with biotinylated antisense oligonucleotide 
complementary to its 5' end. Subsequently RNA was ligated with the pre-adenylated L3 linker 
using T4 RNA ligase 2 or cyclic phosphate-specific tRNA ligase from Arabidopsis thaliana. 
Reaction products were separated on 6% sequencing polyacrylamide gels and analyzed by 
northern blotting using probes against the L3 linker and U6 snRNA. Larger blots with 
unligated U6 snRNA are presented in Supplementary Fig. S8. After hUSB depletion, relative 
number of U6 snRNA molecules terminated with 2',3'-cyclic phosphate decreases and those 
terminated with OH groups increases, as quantified by Multi Gauge software (F and G). All 
values are averages from three independent experiments and the respective P-values 
calculated with unpaired two-tailed Student’s t-test are presented. Please note that the low 
signal intensity for the tRNA ligase reaction products compared to the T4 reaction was due to 
a lower reaction efficiency. (H) TUTase or RTCD1 activity is not required for the formation 
of the U6 snRNA 3'-end cyclic phosphate. RNA from cells treated with siRNAs against 
TUTase (lanes 5-8) or RTCD1 (lanes 13-16) and from control HeLa cells (lanes 1-4) was 
analyzed using high-resolution northern blots. The RNA phosphorylation status was 
determined as described in (A). (I) Depletion of hUSB1 or TUTase does not change the 
stability of mature U6 snRNA. High-resolution northern blot analysis of RNA from cells 
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treated with siRNAs against hUSB1 (lanes 1-2), both hUSB1 and TUTase (lanes 3-4), and 
from control cells (lanes 5-6) after 2 h of actinomycin-D treatment is shown. The 
oligouridylated transcripts are more stable compared to mature forms and hence accumulate 
(lanes 2 and 6). Note that shorter precursor transcripts are eliminated after actinomycin-D 
treatment (lanes 2, 4, 6).  
Figure 5. hUSB1 knockdown does not significantly change the half-life of human U6 
snRNA nor its in vitro splicing activity.  (A) Northern blot analysis of RNA transcripts after 
thiouridine labeling of HeLa cells in vivo. Total RNA from control cells (lanes 1-3) and cells 
treated with siRNA1 (lanes 4-6) and siRNA2 (lanes 7-9) was biotinylated and captured with 
streptavidine beads. Captured RNA was separated on 6% polyacrylamide gels, blotted and 
hybridized against U6 snRNA and 5S rRNA. Quantitative analyses were performed with 
Multi Gauge software, as described in Materials and Methods. (B) Graph shows 
measurements of the U6 snRNA half-life in control and siRNA-treated HeLa cells. The values 
are averages from three independent experiments. (C) hUSB1 depletion slightly affects the in 
vitro splicing activity. Nuclear extracts from HeLa cells after hUsb1 depletion (lanes 6-10) 
exhibited a slightly decreased splicing activity compared to extracts from control cells (lanes 
1-5). The reactions were carried out for 90 min, after which RNA was purified, fractionated 
on 15% polyacrylamide gels, and detected by autoradiography. 
Figure 6. USB1 encodes a putative phosphodiesterase which potential catalytic activity is 
essential for its function. (A) A 3D model of the hUSB1 protein. Invariant catalytic 
histidines and serines from HXS/T motifs are shown in red, whereas other conserved residues 
potentially responsible for substrate binding are shown in magenta. (B) The electrostatic 
potential surface for hUSB1 suggests that the terminal lobe has the ability to bind nucleic 
acids. Negatively-charged regions are colored in red and positively charged regions are 
colored in blue (ranging from -25 kT up to 25 kT). The protein is in the same orientation as in 
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(A). Please see Supplementary Figure S10 for more details. (C) Usb1 belongs to the 2H 
phosphodiesterase superfamily. Multiple sequence alignments of USB1 family representatives 
and selected distantly-related 2H phosphodiesterase structures. Numbers of the residues that 
are not shown are specified in parentheses. Residue conservation is denoted by the following 
scheme: uncharged, highlighted in yellow; charged or polar, highlighted in gray; small, letters 
in red; invariant catalytic residues of HXT/S motifs, highlighted in red. Locations of predicted 
(hUSB1) and observed (PDB, 1VGJ) secondary structure elements are marked above the 
corresponding sequences. Hs, Homo sapiens; Sc, Saccharomyces cerevisiae; Os, Oryza 
sativa; Ao, Aspergillus oryzae; Rn, Rattus norvegicus; Am, Apis mellifera; Pf, Plasmodium 
falciparum; Mm, Mus musculus; Dm, Drosophila melanogaster; At, Arabidopsis thaliana; 
Ph, Pyrococcus horikoshii; Tt, Thermus thermophilus. (D) Complementation assay reveals 
that the Usb1 catalytic mutant cannot restore cell growth. Plasmids containing either wt or 
H133A,  H231A mutant versions of the USB1 gene were transformed into GAL::USB1 strain. 
Resulting strains were plated on permissive (YPGAL) and restrictive (YPD) medium. (E)   
Expression of siRNA insensitive WT hUSB1 mRNA, but not H208A hUSB1 mutant mRNA, 
leads to partial rescue of the molecular phenotype caused by hUSB1 depletion. HEK293 
stable cell lines expressing constructs under the control of a tetracycline-regulated promoter, 
including hUsb1 mRNA resistant to siRNA (si1Res hUsb1) or its corresponding H208A 
mutant mRNA (H208A si1Res) as well as hUsb1 mRNA sensitive to siRNA (hUsb1) or its 
corresponding H208A mutant mRNA (hUsb1 H208A), were transfected with siRNA against 
hUSB1 and then induced with tetracycline. Cells were collected 2 and 4 days after 
transfection and U6 snRNA was detected by high resolution northern blots (lines 5-8 and 17-
20). Untransfeced cells (lines 1-4 and 13-16) and uninduced cells (lines 9-12 and 21-24) were 
used as controls.   
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(F) Proposed reaction mechanism catalyzed by hUSB1. The nucleophilic attack on the 
phosphate group results in the formation of a cyclic phosphate moiety. Groups involved in 
first and second steps of the reaction are shown in green and magenta, respectively, whereas 
the catalytic residues are denoted in blue. 
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